Rapidly climbing sales of the new obesity drug Zepbound and its counterpart for diabetes, Mounjaro, pushed Eli Lilly to a better-than-expected first-quarter profit.
The drugmaker also hiked its sales and earnings forecast for 2024 beyond Wall Street’s expectations even as it hustles to boost manufacturing and catch up to surging demand for the drugs.
Lilly said it was still dealing with supply issues that also hampered the company in the fourth quarter. Company officials expect that to persist through this year, but they emphasized Tuesday that help was on the way.
They expect significant manufacturing increases to occur, starting in the back half of the year.
CEO David Ricks told analysts Tuesday that Lilly was undergoing “the most ambitious expansion plan in our company’s history.”
Indianapolis-based Eli Lilly and Co. recorded $517 million in sales from Zepbound, which received approval from U.S. regulators last November. Total Mounjaro sales more than tripled to $1.81 billion from $568 million in last year’s quarter.
Related articles:
Related suggestion:
Autumn scenery at Pofengling Scenic Area in BeijingChina strives to build stronger rural tourismWorld Wetlands Day: A glimpse of China's earth’s kidneysBirds forage at beach in Kuwait CitySW China's Yunnan makes great efforts to protect wildlife speciesAnimals eat Halloween pumpkins in Zoo Budapest and Botanical GardenXi Sends Congratulatory Letter to General Assembly of Alliance for Cultural Heritage in AsiaChina's tourism sector embraces continuous recoveryPeople go outside to enjoy scenery of flowers in many parts of ChinaAzalea flowers enter blooming season in Guizhou, SW China
3.4716s , 6500.75 kb
Copyright © 2024 Powered by Lilly rides Mounjaro, Zepbound to better ,Earthly Exploits news portal